<DOC>
	<DOCNO>NCT02380287</DOCNO>
	<brief_summary>This open label , phase 1 , `` 3+3 '' dose escalate study tolerability , safety , pharmacokinetics immunogenicity single subcutaneous injection novel monoclonal antibody human IL-17 - BCD-085 . The study enroll 37 healthy male volunteer .</brief_summary>
	<brief_title>First-in-human Study Evaluate Safety , Tolerability Pharmacokinetics Various Doses BCD-085 Healthy Subjects</brief_title>
	<detailed_description>IL-17 new potential therapeutic target play important role pathogenesis several autoimmune disorder include psoriasis , rheumatoid arthritis , possibly - SLE MS. BCD-085 novel humanize monoclonal antibody human IL17 develop JCS BIOCAD ( Russia ) first step clinical evaluation . BCD-085-1 study first-in-human clinical trial intend evaluate tolerability , safety , pharmacokinetics immunogenicity BCD-085 use single step-by-step escalate subcutaneous dose healthy male volunteer . During study expect determine diapason safety dose BCD-085 ( incl . MTD ) thereafter evaluate phase 2 study .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>sing informed consent male gender 1845 year age inclusively BMI between18.530.0 kg/sq.m . absence sings hepatic , renal , gastrointestinal , cardiovascular , endocrine , respiratory , immunologic , hematologic , dermatologic , neurologic abnormality screen or/and anamnesis parameter complete blood count , blood biochemistry , urinalysis exceed reference value , use Study site laboratory . Evaluation require laboratory parameter must perform within 14 day randomization normal hemodynamic parameter : systolic BP 100 139 mm Hg , diastolic BP 60 90 mm Hg , heart rate 60 90 b/min absence chronic infection ( HIV , syphilis , hepatitis В С , tuberculosis ) chronic inflammation absence infection within 4 week randomization absence mental disorder condition ( incl . depression ) , may affect ability participant follow Protocol health wellbeing ( volunteer 's opining opinion ) least 30 day randomization . absence alcohol drug addiction sign ( incl . history addiction ) . Consent use alcohol within 24 hour injection BCD085 ; volunteer 's ability follow Protocol procedure consent volunteer sexual partner childbearing potential use adequate contraception screen period main study part ( 14 day randomization 61 day SC injection ) . This requirement applicable surgically sterilize volunteer . Adequate contraception include use one barrier method combination spermicide , intrauterine device / oral contraceptive sexual partner history use monoclonal antibody IL17 know severe allergy ( anaphylaxis multidrug intolerance ) know intolerance medicine contain monoclonal antibody ( murine , humanize , human ) excipients BCD085 major surgery within 30 day prior screen severe infection ( require hospitalization , parenteral use antimicrobial agent ) within 6 month prior date BCD085 injection systemic use antimicrobial within 2 month prior date BCD085 injection 4 episode respiratory tract infection within 6 month prior screen examination presence disorder may affect pharmacokinetics BCD085 history fever equal exceed 40 degree Celsius history hepatic transaminase increase 2.5 x ULN history seizure actual prior depression , suicidal tendency use medicine , vitamin , biologically active additive within 14 day prior date BCD085 injection use medicine affect hemodynamics hepatic function within 30 day prior date BCD085 injection use medicine may influence immune system within 30 day prior date BCD085 injection vaccination within 4 week prior date BCD085 injection smoke exceeds 10 cigarette per day use alcohol , exceed 10 unit per week ( 1 alcohol unit equal ½ l beer ( 1 pint ) , 200 ml vine , 50 ml alcohol donation 450 ml blood plasma within 2 month prior randomization . simultaneous participation clinical trial , well former participation clinical trial within 3 month study initiation . previous participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>interleukin-17</keyword>
	<keyword>maximum tolerate dose</keyword>
	<keyword>novel monoclonal antibody</keyword>
</DOC>